GT Biopharma, Inc. Files 2023 Annual Report on Form 10-K
Ticker: GTBP · Form: 10-K · Filed: Mar 26, 2024 · CIK: 109657
Sentiment: neutral
Topics: GT Biopharma, 10-K, Annual Report, Pharmaceuticals, SEC Filing
TL;DR
<b>GT Biopharma, Inc. has filed its 2023 annual report (10-K) detailing its financial performance and business operations.</b>
AI Summary
GT Biopharma, Inc. (GTBP) filed a Annual Report (10-K) with the SEC on March 26, 2024. GT Biopharma, Inc. filed its 2023 Form 10-K on March 26, 2024. The company was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/. The filing covers the fiscal year ending December 31, 2023. GT Biopharma is incorporated in Delaware and operates in the Pharmaceutical Preparations industry (SIC 2834). The company's principal business address is in Brisbane, California.
Why It Matters
For investors and stakeholders tracking GT Biopharma, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of GT Biopharma's financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. Understanding the company's historical name changes and corporate evolution can provide context for its current business strategy and market positioning within the pharmaceutical sector.
Risk Assessment
Risk Level: medium — GT Biopharma, Inc. shows moderate risk based on this filing. The company's financial performance and operational status are not detailed in the provided filing excerpt, making it difficult to assess its current financial health or growth trajectory, which introduces uncertainty for investors.
Analyst Insight
Investors should review the full 10-K filing to understand GT Biopharma's financial statements, risk factors, and management's discussion and analysis to make informed investment decisions.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period)
- 2024-03-26 — Filing Date (Date of submission)
- 1994-09-16 — Name Change Date (Former company name change)
- 1992-07-03 — Name Change Date (Former company name change)
- 1985-03-12 — Name Change Date (Former company name change)
Key Players & Entities
- GT Biopharma, Inc. (company) — Filer name
- OXIS INTERNATIONAL INC (company) — Former company name
- DDI PHARMACEUTICALS INC (company) — Former company name
- DIAGNOSTIC DATA INC /DE/ (company) — Former company name
- 2023-12-31 (date) — Fiscal year end
- 2024-03-26 (date) — Filing date
- Brisbane, CA (location) — Business address
- 2834 (industry_code) — Standard Industrial Classification
FAQ
When did GT Biopharma, Inc. file this 10-K?
GT Biopharma, Inc. filed this Annual Report (10-K) with the SEC on March 26, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by GT Biopharma, Inc. (GTBP).
Where can I read the original 10-K filing from GT Biopharma, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by GT Biopharma, Inc..
What are the key takeaways from GT Biopharma, Inc.'s 10-K?
GT Biopharma, Inc. filed this 10-K on March 26, 2024. Key takeaways: GT Biopharma, Inc. filed its 2023 Form 10-K on March 26, 2024.. The company was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.. The filing covers the fiscal year ending December 31, 2023..
Is GT Biopharma, Inc. a risky investment based on this filing?
Based on this 10-K, GT Biopharma, Inc. presents a moderate-risk profile. The company's financial performance and operational status are not detailed in the provided filing excerpt, making it difficult to assess its current financial health or growth trajectory, which introduces uncertainty for investors.
What should investors do after reading GT Biopharma, Inc.'s 10-K?
Investors should review the full 10-K filing to understand GT Biopharma's financial statements, risk factors, and management's discussion and analysis to make informed investment decisions. The overall sentiment from this filing is neutral.
Key Dates
- 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
- 2024-03-26: Filing Date — Date GT Biopharma, Inc. submitted its 10-K filing.
Glossary
- 10-K
- An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the official annual financial and business overview for GT Biopharma, Inc.)
- Fiscal Year End
- The last day of a company's accounting year. (Indicates the period covered by the financial statements in the 10-K filing.)
Filing Stats: 4,517 words · 18 min read · ~15 pages · Grade level 14.5 · Accepted 2024-03-26 17:00:40
Key Financial Figures
- $0.001 — ges on which Registered Common Stock, $0.001 Par Value GTBP Nasdaq Capital Mark
Filing Documents
- form10-k.htm (10-K) — 1495KB
- ex10-77.htm (EX-10.77) — 2KB
- ex10-78.htm (EX-10.78) — 3KB
- ex10-81.htm (EX-10.81) — 4KB
- ex23-1.htm (EX-23.1) — 4KB
- ex31-1.htm (EX-31.1) — 19KB
- ex31-2.htm (EX-31.2) — 19KB
- ex32-1.htm (EX-32.1) — 5KB
- ex32-2.htm (EX-32.2) — 6KB
- ex10-77_001.jpg (GRAPHIC) — 460KB
- ex10-77_002.jpg (GRAPHIC) — 350KB
- ex10-78_001.jpg (GRAPHIC) — 460KB
- ex10-78_002.jpg (GRAPHIC) — 313KB
- ex10-78_003.jpg (GRAPHIC) — 345KB
- ex10-81_001.jpg (GRAPHIC) — 512KB
- ex10-81_002.jpg (GRAPHIC) — 352KB
- ex10-81_003.jpg (GRAPHIC) — 356KB
- form10-k_001.jpg (GRAPHIC) — 11KB
- form10-k_002.jpg (GRAPHIC) — 8KB
- form10-k_003.jpg (GRAPHIC) — 20KB
- form10-k_004.jpg (GRAPHIC) — 15KB
- form10-k_005.jpg (GRAPHIC) — 21KB
- form10-k_006.jpg (GRAPHIC) — 28KB
- form10-k_010.jpg (GRAPHIC) — 57KB
- form10-k_011.jpg (GRAPHIC) — 61KB
- form10-k_012.jpg (GRAPHIC) — 291KB
- 0001493152-24-011332.txt ( ) — 11739KB
- gtbp-20231231.xsd (EX-101.SCH) — 47KB
- gtbp-20231231_cal.xml (EX-101.CAL) — 48KB
- gtbp-20231231_def.xml (EX-101.DEF) — 207KB
- gtbp-20231231_lab.xml (EX-101.LAB) — 413KB
- gtbp-20231231_pre.xml (EX-101.PRE) — 322KB
- form10-k_htm.xml (XML) — 704KB
Business
Business 1 Item 1A.
Risk Factors
Risk Factors 11 Item 1B. Unresolved Staff Comments 34 Item 1C. Cybersecurity 34 Item 2.
Properties
Properties 34 Item 3.
Legal Proceedings
Legal Proceedings 34 Item 4. Mine Safety Disclosures 34 PART II 35 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 35 Item 6. [Reserved] 36 Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 43 Item 8.
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 43 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 43 Item 9A.
Controls and Procedures
Controls and Procedures 43 Item 9B. Other Information 44 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 44 PART III 44 Item 10. Directors, Executive Officers and Corporate Governance 44 Item 11.
Executive Compensation
Executive Compensation 44 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 44 Item 13. Certain Relationships and Related Transactions, and Director Independence 44 Item 14. Principal Accounting Fees and Services 44 PART IV 45 Item 15. Exhibits and Financial Statement Schedules 45 Item 16. Form 10-K Summary 48 SUMMARY
RISK FACTORS
RISK FACTORS Our business involves significant risks. Below is a summary of the material risks that our business faces, which makes an investment in our securities speculative and risky. This summary does not address all these risks. These risks are more fully described below under the heading "Risk Factors" in Part I, Item 1A of this annual report on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investment. In addition, there are also additional risks not described below that are either not presently known to us or that we currently deem immaterial, and these additional risks could also materially impair our business, operations or market price of our common stock. Our business is at an early stage of development and we may not develop therapeutic products that can be commercialized. We have a history of operating losses and we expect to continue to incur losses for the foreseeable future and we may never generate revenue or achieve profitability. If we fail to meet our obligations under our license agreements, we may lose our rights to key technologies on which our business depends. Our reliance on the activities of our non-employee consultants, research institutions and scientific contractors, whose activities are not wholly within our control, may lead to delays in development of our proposed products. We have limited clinical testing and regulatory capabilities, and human clinical trials are subject to extensive regulatory requirements, very expensive, time-consuming and difficult to design and implement. Our products may fail to achieve necessary safety and efficacy endpoints during clinic